Evidence map›Paper›PMID 38473309›Full record

ArticleCancers2024

Advancing Precision Oncology in Hereditary Paraganglioma-Pheochromocytoma Syndromes: Integrated Interpretation and Data Sharing of the Germline and Tumor Genomes.

Huma Q Rana, Diane R Koeller, McKenzie Walker, Busra Unal, Alison Schwartz Levine, Anu Chittenden, Raymond A Isidro, Connor P Hayes, Monica D Manam, Ryan M Buehler and 6 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Huma Q RanaDivision of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Diane R KoellerDivision of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0003-1217-9514
McKenzie WalkerDivision of Genetics, Brigham and Women's Hospital, Boston, MA 02115, USA.
Busra UnalDivision of Genetics, Brigham and Women's Hospital, Boston, MA 02115, USA.ORCID 0000-0002-2056-2604
Alison Schwartz LevineDivision of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Anu ChittendenDivision of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Raymond A IsidroDepartment of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Connor P HayesDivision of Genetics, Brigham and Women's Hospital, Boston, MA 02115, USA.
Monica D ManamDepartment of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Ryan M BuehlerDivision of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Danielle K ManningDepartment of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Justine A BarlettaHarvard Medical School, Boston, MA 02115, USA.
Jason L HornickHarvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-6475-8345
Judy E GarberDivision of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Arezou A GhazaniHarvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-4439-8554
Int2grate Oncology Consortium
Brigham and Women's Hospital · USDana-Farber Cancer Institute · USHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Standard methods of variant assessment in hereditary cancer susceptibility genes are limited by the lack of availability of key supporting evidence. In cancer, information derived from tumors can serve as a useful source in delineating the tumor behavior and the role of germline variants in tumor progression. We have previously demonstrated the value of integrating tumor and germline findings to comprehensively assess germline variants in hereditary cancer syndromes. Building on this work, herein, we present the development and application of the INT

Indexed as

germline VUShereditary paraganglioma–pheochromocytoma syndromes (HPPGLs)INT2GRATEINT2GRATE Oncology ConsortiumPCCPGLsomatic and germline integrationtumor signature profile

Identifiers

PMID38473309
PMCPMC10931192
OpenAlexW4392169453

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.